Dova Pharmaceuticals, Inc. Common Stock
DOVA
DOVA was delisted on the 11th of November, 2019.
66 hedge funds and large institutions have $131M invested in Dova Pharmaceuticals, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 20 increasing their positions, 18 reducing their positions, and 9 closing their positions.
100% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 9
72% more capital invested
Capital invested by funds: $75.9M → $131M (+$54.7M)
12% more funds holding
Funds holding: 59 → 66 (+7)
11% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 18
17% less call options, than puts
Call options by funds: $3.09M | Put options by funds: $3.73M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$4.06M |
| 2 |
SMH
Sanders Morris Harris
Houston,
Texas
|
+$2.28M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.67M |
| 4 |
Morgan Stanley
New York
|
+$1.57M |
| 5 |
SCM
Sio Capital Management
New York
|
+$1.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.89M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$2.07M |
| 3 |
BlackRock
New York
|
-$1.49M |
| 4 |
SIM
Spark Investment Management
New York
|
-$715K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$309K |
DOVA Hedge Fund Activity: Q2 2019 in Review
66 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Dova Pharmaceuticals, Inc. Common Stock (DOVA) for Q2 2019, worth a combined $131M — up 72% from $75.9M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new DOVA positions and 9 closed out — a net gain of 9 holders — while 20 added to existing stakes and 18 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $4.06M. The largest seller was Fidelity Investments, cutting an estimated $4.89M.
- 66 institutional investors held Dova Pharmaceuticals, Inc. Common Stock (DOVA) as of Q2 2019, up from 59 in Q1 2019.
- Funds reported $131M of Dova Pharmaceuticals, Inc. Common Stock stock for Q2 2019, up 72% quarter-over-quarter.
- 18 funds opened new Dova Pharmaceuticals, Inc. Common Stock positions in Q2 2019 and 9 closed out, a net change of +9 holders.
- The largest Dova Pharmaceuticals, Inc. Common Stock buyer in Q2 2019 was Perceptive Advisors, an estimated $4.06M added.
- The largest Dova Pharmaceuticals, Inc. Common Stock seller in Q2 2019 was Fidelity Investments, an estimated $4.89M sold.
Based on aggregated 13F filings for Q2 2019.